Premium
Conjugated Linoleic Acid Reduces Body Weight and Body Fat in Postmenopausal Women with Type 2 Diabetes
Author(s) -
Norris Leigh,
Colleen Angela,
Asp Michelle,
Liu LiFen,
Hsu Jason,
Li Dongmei,
Bell Doris,
Osei Kwame,
Jackson Rebecca,
Belury Martha
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.1090.5
Subject(s) - medicine , weight loss , body mass index , type 2 diabetes , endocrinology , lean body mass , conjugated linoleic acid , crossover study , waist , obesity , diabetes mellitus , physiology , linoleic acid , body weight , fatty acid , chemistry , placebo , alternative medicine , pathology , organic chemistry
Post‐menopausal women are at risk for weight gain and type 2 diabetes (T2DM). Conjugated linoleic acid (CLA) reduces fat mass in mice, but results in humans have been inconsistent. In a 36‐ week controlled, double masked, crossover study we sought to determine if CLA reduces body weight and alters body composition. Fifty‐ five subjects were randomized into two groups, receiving 6.4 g mixed isomer CLA and 1.6 g safflower oil (SAF) or 8.0g SAF daily Analysis of results at individual 5% level of significance were as follows. Mean body weight loss in the CLA group was 0.48 ±0.23 kg in diet period one (DP1) and 0.42± 0.19 kg in diet period two (DP2). Body mass index (BMI) was significantly lower with CLA compared to SAF during both diet periods, with a trend toward weight loss after 8 weeks of supplementation. Body fat mass (BFM) was significantly lower in the CLA group without changes in lean body mass (LBM). SAF did not affect BFM, while SAF increased LBM in both diet periods. There was no evidence of change in sagittal abdominal diameter or waist‐ to‐ hip ratio, indexes of visceral obesity. The changes in BMI and BFM were not associated with dietary energy intake. Reports of adverse events did not differ between groups. In conclusion, CLA given at a dose of 6.4g/day over a 16 week period causes a significant reduction in BMI and BFM while preserving LBM in obese postmenopausal women with T2DM. Supported by Cognis GmbH